While a HERA trial sub-analysis, found an inverse correlation between FISH ratio and ER-positivity, of note, results from the N9831 trial demonstrated a lower rate of relapse in ER- positive BC than in hormone receptor-negative tumors [32]. Here, ERAL1 is linked to breast cancer.